3 Australian Mining Stocks With Strong Profits and Balance Sheet Questions

Global bond yields rose recently as markets reacted to higher oil prices and inflation worries. That push and pull between energy costs and interest rate expectations keeps many large caps on a tight leash. It also helps Financially Fit Penny Stocks stand out: you get smaller companies where balance sheet strength matters most. This article highlights three stocks from the screener that could deserve a closer look now.

The three Financially Fit Penny Stocks highlighted below are only a starting sample. The full screen surfaced 402 more companies with equally compelling financial stories that are not covered in this article. Head straight into the Financially Fit Penny Stocks screener to identify, analyze, and focus on the penny stocks that best match your risk profile and conviction level.

Ora Banda Mining (ASX:OBM)

Ora Banda Mining is a Subiaco based gold producer and explorer focused on the Davyhurst Gold Project north west of Kalgoorlie, with additional exposure to nickel, copper and lithium. The business currently generates all of its A$554 million revenue from gold production and exploration in Australia. The stock sits in mid cap territory with a market value of about A$2.62b.

Ora Banda Mining sits at the intersection of strong operating momentum and rich growth optionality. The company reports very high current profitability with a 41.8% net margin and ROE of 59.4%, supported by record gold production and a much larger Davyhurst resource and reserve base that now underpins a longer mine life. At the same time, the stock is priced well below one DCF estimate of fair value and trades on a modest P/E versus peers, which can appeal to value focused investors. The catch is that the business leans heavily on external debt funding and shows a high level of non cash earnings, so investors need to be comfortable with balance sheet and quality of profit risks before looking more deeply at the business.

Ora Banda Mining’s high margins and strong ROE suggest a story that might not be fully priced in, yet the debt load and non cash earnings raise questions. Get the 4 key rewards and 1 important major warning sign

Build your own high margin and value shortlist

Ora Banda Mining and the other two stocks here are just a few examples that surfaced using our screening tools. Use our customisable Screener to mix filters like valuation, profitability, balance sheet strength and risk, or start with any of our curated Investing Ideas for ready made shortlists.

Alkane Resources (ASX:ALK)

Alkane Resources is a West Perth based miner that produces gold and antimony from three operating mines in Australia and Sweden, and also explores for copper, nickel, zinc and silver while investing in junior gold projects. The company has grown into a multi mine platform and sits in the gold producer camp rather than early stage exploration. The stock has a market value of about A$2.19b.

Alkane Resources brings together three producing mines, exposure to both gold and antimony, and the long term potential of the Boda Kaiser gold copper project. It trades at a large discount to one cash flow based valuation estimate and carries a P/E near sector levels. Earnings and margins look strong, with net profit margin at 22.5% and earnings growth forecasts well into double digits, yet the balance sheet leans on external borrowing and the board is relatively young and less independent. For investors who can accept that funding and governance risk mix, the combination of record production, a growing resource base at assets like Björkdal and Costerfield, and a deep exploration pipeline could make Alkane a stock worth watching closely.

Alkane Resources combines multi mine production, gold and antimony exposure, and the Boda Kaiser story, yet the full picture still feels incomplete. Scan the analyst forecasts for Alkane Resources to see what the current outlook might be missing.

Sigma Healthcare (ASX:SIG)

Sigma Healthcare is a century old Australian pharmacy group that franchises brands such as Chemist Warehouse, Amcal and Discount Drug Stores, while also running a large wholesale and logistics operation for community pharmacies and drug manufacturers. The company generates about A$9.55b in revenue, all from its Healthcare segment, and primarily within Australia. Sigma Healthcare has a market value of roughly A$34.16b.

Investors looking at Sigma Healthcare may focus on the scale of its pharmacy and logistics network, but the story is more nuanced. Recent analysis cites earnings growth expectations of around 15% a year and revenue that is forecast to outpace the wider Australian market. At the same time, net margin has been reported at 6.3% and returns on equity have been described as moderate. In addition, the stock is noted as trading on a relatively high earnings multiple and facing governance questions, including a relatively inexperienced board and management team and higher risk funding. Sigma’s decision in mid 2026 to walk away from a potential Boots takeover has also been interpreted as a sign of tighter capital discipline, which could influence how investors weigh the trade off between growth, risk and price.

Sigma Healthcare’s growth story and capital discipline may be masking a deeper shift in how its earnings quality is perceived. Tap into the analysis report for Sigma Healthcare and see what could change that perception next.

Seeking Fresh Alternatives Beyond These Picks

Fresh stock ideas often move from quiet to flying under the radar in a hurry. Spot potential breakouts before the crowd, while it matters. Act now.

• Chase resilient compounding potential with a curated group of companies in the 10 resilient stocks with low risk scores before current pricing and risk profiles get fully caught by the wider market.
• Ride structural themes around electrification, AI and data growth with the under the radar 36 power grid technology and infrastructure stocks while sentiment and momentum are still forming.
• Target long term demand for critical metals by scanning the hand picked 9 top copper producer stocks and position before capital flows and headlines catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com